BNXT Share Price Performance
Recent BNXT News & Updates
No updates
BioNxt Solutions Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.049
- Gross Margin
- 100.00%
- Net Profit Margin
- -24,999.89%
- Debt/Equity Ratio
- -88.3%
BioNxt Solutions Inc. Competitors
About BNXT
- Founded
- 2017
- Employees
- n/a
- CEO
- WebsiteView website
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new active pharmaceutical production and evaluation, including precision transdermal and oral dissolvable drug formulations; infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Canadian Market Performance
- 7 Days: 0.9%
- 3 Months: 11.7%
- 1 Year: 17.4%
- Year to Date: 10.1%
The Consumer Staples sector gained 3.6% while the market remained flat over the last week. Meanwhile, the market is actually up 17% over the past year. Looking forward, earnings are forecast to grow by 12% annually. Market details ›
The tide is turning for UK & European markets. Index ETFs won’t cut it since sector spreads are massive. Picking the right companies matters now more than ever.
Continue readingLast Week
